{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:47:51Z","timestamp":1793130471639,"version":"4.5.0"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Continuum"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1212\/con.0000000000000956","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T18:46:45Z","timestamp":1622227605000},"page":"597-612","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Acute Migraine Treatment"],"prefix":"10.1212","volume":"27","author":[{"given":"Jessica","family":"Ailani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2001.041007646.x"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2004.00893.x"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001256"},{"issue":"15","key":"e_1_3_1_5_2","article-title":"Acute treatment management gaps in people with migraine: results of the CaMEO study","volume":"94","author":"Buse DC","year":"2020","unstructured":"Buse DC, Nahas SJ, Schwedt TJ, . Acute treatment management gaps in people with migraine: results of the CaMEO study. Neurology 2020;94(S15).","journal-title":"Neurology"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.12482"},{"key":"e_1_3_1_7_2","volume-title":"Migraine care across the healthcare landscape in the United States among those with 4 or greater migraine headache days per month: results of the OVERCOME study","author":"Buse DC","unstructured":"Buse DC, Nicholson RA, Araujo AB, . Migraine care across the healthcare landscape in the United States among those with 4 or greater migraine headache days per month: results of the OVERCOME study. Abstract presented at: Annual Scientific Meeting of the American Headache Society; July 11-14, 2019; Philadelphia, PA."},{"issue":"5","key":"e_1_3_1_8_2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1017\/S0317167100118943","article-title":"Canadian Headache Society Guideline: acute drug therapy for migraine headache","volume":"40","author":"Worthington WI","year":"2013","unstructured":"Worthington WI, Pringsheim T, Gawel M, . Canadian Headache Society Guideline: acute drug therapy for migraine headache. Can J Neurol Sci 2013;40(5 suppl 3):S1\u2013S80.","journal-title":"Can J Neurol Sci"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.12499"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.13456"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.20.2599"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.22.3486"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2020.1767402"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1909"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00442.x"},{"key":"e_1_3_1_16_2","unstructured":"Singh RBH VanderPluym JH Morrow AS . Evidence summary. In: Acute treatments for episodic migraine. Agency for Healthcare Research and Quality (US) Report No 21-EhC009. Published 2020. Accessed April 2 2021. ncbi.nlm.nih.gov\/books\/NBK566251\/"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.12233"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2011.02032.x"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0881-z"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.13309"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.12601"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102416660552"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413480756"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.12404"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.12198"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.13642"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2004.04078.x"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.13179"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.5144"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.13700"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413483372"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2011.02041.x"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.00826.x"},{"key":"e_1_3_1_34_2","volume-title":"Migranal nasal spray. Prescribing information","year":"2020","unstructured":"Migranal nasal spray. Prescribing information. Bausch Health Companies Inc; 2020. Revised July 2019. Accessed April 2, 2021. bauschhealth.com\/Portals\/25\/Pdf\/PI\/Migranal-PI.pdf"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.36.7.995"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1997.3703129.x"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.spen.2015.08.004"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006641"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz134"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1420-5"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419864132"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-1044-6"},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2732"},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1543"},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.15.5731"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2019.1618830"},{"key":"e_1_3_1_47_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813049"},{"key":"e_1_3_1_48_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.16711"},{"key":"e_1_3_1_49_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811090"},{"key":"e_1_3_1_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31606-X"},{"issue":"15","key":"e_1_3_1_51_2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1212\/WNL.94.15_supplement.166","article-title":"An optional second dose of ubrogepant is effective in achieving 2-hour pain freedom in the acute treatment of migraine","volume":"94","author":"Ailani J","year":"2020","unstructured":"Ailani J, Blumenfeld A, Klein B, . An optional second dose of ubrogepant is effective in achieving 2-hour pain freedom in the acute treatment of migraine. Neurology 2020;94(15 suppl):166.","journal-title":"Neurology"},{"key":"e_1_3_1_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.13682"},{"issue":"15","key":"e_1_3_1_53_2","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1212\/WNL.94.15_supplement.4829","article-title":"Long-term safety of rimegepant 75 mg for the acute treatment of migraine","volume":"94","author":"Croop R","year":"2020","unstructured":"Croop R, Berman G, Kudrow D, . Long-term safety of rimegepant 75 mg for the acute treatment of migraine. Neurology 2020;94(15 suppl):4829.","journal-title":"Neurology"},{"issue":"15","key":"e_1_3_1_54_2","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1212\/WNL.94.15_supplement.2141","article-title":"Cardiovascular safety of rimegepant 75 mg in 3 randomized clinical trials and systematic evaluations from in vitro, ex vivo, and in vivo nonclinical assays (2141)","volume":"94","author":"Conway C","year":"2020","unstructured":"Conway C, Croop R, Dubowchik G, . Cardiovascular safety of rimegepant 75 mg in 3 randomized clinical trials and systematic evaluations from in vitro, ex vivo, and in vivo nonclinical assays (2141). Neurology 2020;94(15 suppl) 2141.","journal-title":"Neurology"},{"key":"e_1_3_1_55_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419884943"},{"issue":"15","key":"e_1_3_1_56_2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1212\/WNL.94.15_supplement.107","article-title":"Safety and efficacy of ubrogepant in participants with moderate to high cardiovascular risk","volume":"94","author":"Severt L","year":"2020","unstructured":"Severt L, Silberstein SD, Blumendfeld AM, . Safety and efficacy of ubrogepant in participants with moderate to high cardiovascular risk. Neurology 2020;94(15 suppl):107.","journal-title":"Neurology"},{"key":"e_1_3_1_57_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25831"},{"key":"e_1_3_1_58_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418811573"},{"key":"e_1_3_1_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70054-5"},{"key":"e_1_3_1_60_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005857"},{"key":"e_1_3_1_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.13551"},{"key":"e_1_3_1_62_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.13586"},{"key":"e_1_3_1_63_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419828967"},{"key":"e_1_3_1_64_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009324"},{"key":"e_1_3_1_65_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-004-0308-2"}],"container-title":["Continuum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1212\/CON.0000000000000956","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T14:02:36Z","timestamp":1752156156000},"score":1,"resource":{"primary":{"URL":"https:\/\/continuum.aan.com\/doi\/10.1212\/CON.0000000000000956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1212\/CON.0000000000000956"],"URL":"https:\/\/doi.org\/10.1212\/con.0000000000000956","relation":{},"ISSN":["1080-2371","1538-6899"],"issn-type":[{"value":"1080-2371","type":"print"},{"value":"1538-6899","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}